Simplify Asset Management Inc. Has $2.23 Million Stake in Pacira BioSciences, Inc. $PCRX

Simplify Asset Management Inc. raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 91.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 86,261 shares of the company’s stock after purchasing an additional 41,315 shares during the period. Simplify Asset Management Inc. owned 0.20% of Pacira BioSciences worth $2,232,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Pacira BioSciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after acquiring an additional 1,165 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Pacira BioSciences by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after acquiring an additional 367,869 shares during the period. Strs Ohio acquired a new position in shares of Pacira BioSciences during the 1st quarter valued at $75,000. Marshall Wace LLP acquired a new position in shares of Pacira BioSciences during the 2nd quarter valued at $4,550,000. Finally, Sei Investments Co. lifted its position in shares of Pacira BioSciences by 35.3% during the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock valued at $606,000 after acquiring an additional 6,609 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Buying and Selling at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,261 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider owned 223,640 shares in the company, valued at $5,103,464.80. This represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total transaction of $325,595.56. Following the completion of the sale, the chief financial officer owned 105,341 shares of the company’s stock, valued at approximately $2,650,379.56. The trade was a 10.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 28,261 shares of company stock valued at $702,610. Company insiders own 6.40% of the company’s stock.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $23.35 on Monday. The firm has a market capitalization of $918.82 million, a PE ratio of 194.60 and a beta of 0.32. The firm has a fifty day simple moving average of $23.47 and a two-hundred day simple moving average of $23.27. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The business had revenue of $177.38 million for the quarter, compared to the consensus estimate of $171.80 million. During the same quarter last year, the firm posted $0.65 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Analysts forecast that Pacira BioSciences, Inc. will post 1.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on PCRX. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Barclays dropped their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 26th. Royal Bank Of Canada boosted their target price on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research report on Friday, May 1st. Wall Street Zen downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC boosted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $29.40.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.